Photo by National Cancer Institute on Unsplash
A new question about cancer screening is drawing attention after an immunology researcher suggested that DNA fragments detected by blood tests could influence the body’s immune response to cancer.
The discussion follows growing interest in the Galleri blood test, which is designed to detect signals associated with more than 50 types of cancer. However, researchers say understanding what these DNA fragments do inside the body could open another area of cancer research.
Joseph A. Bellanti, an immunology researcher at Georgetown University Medical Center, raised the possibility in a letter published by The Washington Post on October 30, 2026.
His argument focuses on whether cancer-associated DNA fragments circulating in the bloodstream could do more than help identify potential signs of disease.
Cancer DNA test raises questions about immune activity
The Galleri test looks for cancer-associated patterns in DNA fragments circulating in the blood. These patterns are known as DNA methylation markers.
DNA methylation involves chemical modifications that influence how genetic information is regulated. Researchers can study these patterns to identify clues about the cells that released the DNA.
However, Bellanti believes scientists should investigate whether these fragments could also influence immune activity.
His concern centers on how certain DNA sequences might affect the body’s ability to recognize and fight cancer cells.
In his letter, Bellanti referenced experimental research he conducted with colleagues at Georgetown University Medical Center and collaborating institutions.
The studies examined selected methylated DNA sequences under specific experimental conditions. Their findings suggested that these sequences could encourage the activity of regulatory T cells.
These immune cells help control inflammation and prevent excessive immune reactions. However, their activity can also create challenges when the body is fighting cancer.
In some circumstances, regulatory T cells can limit the immune system’s ability to attack malignant cells.
How DNA fragments could affect cancer immunity
The research raises an important question about the relationship between cancer-associated DNA and immune defenses.
Cancer cells can release DNA fragments into the bloodstream. These fragments may contain chemical patterns that provide information about the disease.
Scientists have increasingly explored how circulating tumor DNA can help identify cancer-related signals. However, Bellanti wants researchers to examine whether these fragments also have biological effects.
He suggested that certain methylation patterns could potentially encourage immune responses that make it easier for cancer cells to avoid detection.
If future research confirms this possibility, it could change how scientists understand the relationship between cancer and the immune system.
However, the findings do not establish that DNA fragments released by tumors suppress immunity in humans. The research only identifies a possibility that requires further investigation.
This distinction is important because the Galleri test was developed to detect cancer-associated signals. It was not designed to measure how those signals affect immune function.
Could the discovery lead to new cancer treatments?
Bellanti believes further investigation could help researchers identify previously unexplored treatment opportunities.
If scientists establish that certain tumor-derived DNA fragments interfere with immune defenses, they could investigate ways to block those effects.
Such discoveries could eventually help researchers develop treatments that restore the immune system’s ability to recognize and attack cancer cells.
The research could also expand scientific understanding of how tumors interact with their surrounding biological environment.
For now, the proposed connection remains a research question rather than an established medical finding.
The discussion also highlights why scientists must continue evaluating emerging cancer-screening technologies beyond their ability to identify potential disease.
As interest in multi-cancer blood tests grows, understanding the biological activity of the signals they detect could become another important area of investigation.
Bellanti’s argument adds a new dimension to conversations about the Galleri test. It suggests that the DNA fragments circulating in the blood may deserve attention not only as possible indicators of cancer but also as subjects of further immunological research.
For patients and healthcare professionals, the distinction remains important. A promising research hypothesis is not the same as a proven diagnostic benefit or treatment.
The next stage of research will need to establish whether these experimental findings have meaningful implications for cancer development, immune responses and future treatment strategies.
About the Author
